Furthermore, Farr et al. (2016) did not observe any changes in hypothalamic activity after administration of lorcaserin, an agonist of serotonin 5-hydroxytryptamine 2c receptor, being effective in obesity treatment. The gene discussed is HTR2C; the disease is obesity disorder.